Delving into the Latest Updates on Pharmamax Pharmaceuticals Ltd. with Synapse

Overview

Basic Info

Introduction

Changtai Jiangsu Pharmaceutical Co. Ltd is a company that specializes in providing medical products and therapies. They offer a range of products including marketed, production management, and quality management system products. Additionally, they provide a nasal clearing spray for the treatment of allergic and non-allergic rhinitis. The company was established by Zhijun Jiang in 2010 and is based in Taizhou, China.

Tags

Respiratory Diseases

Other Diseases

Infectious Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4
Chemical drugs	1

Top 5 Target	Count

D1 receptor x D2 receptor x SERT	1
β2-adrenergic receptor(Beta-2 adrenergic receptor)	1
IL-6 x Reactive oxygen species	1
Opioid receptors	1

The primary objective was to evaluate the pharmacokinetic characteristics of morphine and naltrexone after a single oral administration of morphine sulfate and naltrexone hydrochloride sustained-release capsules on an empty stomach in Chinese patients with moderate to severe cancer pain. The secondary objective was to evaluate the safety of a single oral administration of morphine sulfate and naltrexone hydrochloride sustained-release capsules in Chinese patients with moderate to severe cancer pain.

Start Date14 Feb 2023

Sponsor / Collaborator

Pharmamax Pharmaceuticals Ltd.

CTR20220404 / CompletedPhase 2

评价丙酮酸钠吸入剂治疗稳定期慢性阻塞性肺疾病（COPD）的疗效和安全性的随机、双盲、安慰剂平行对照多中心Ⅱ期临床研究

[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical study to evaluate the efficacy and safety of sodium pyruvate inhalation in the treatment of stable chronic obstructive pulmonary disease (COPD)

本研究的主要目的是以安慰剂为对照，在加载噻托溴铵粉吸入剂（思力华）的基础上探索不同剂量丙酮酸钠吸入剂连续给药 6 周对稳定期 COPD 受试者的有效性和安全性及剂量效应关系。

[Translation]

The main purpose of this study is to explore the efficacy, safety and dose-effect relationship of different doses of sodium pyruvate inhalation for 6 weeks in subjects with stable COPD, based on tiotropium bromide powder inhalation (Spiriva) as a placebo control.

Start Date28 Mar 2022

Sponsor / Collaborator

Pharmamax Pharmaceuticals Ltd.

100 Clinical Results associated with Pharmamax Pharmaceuticals Ltd.

Login to view more data

0 Patents (Medical) associated with Pharmamax Pharmaceuticals Ltd.

Login to view more data

2

Literatures (Medical) associated with Pharmamax Pharmaceuticals Ltd.

01 Feb 2024·European Journal of Pharmaceutical Sciences

Construction of chrysophanol loaded nanoparticles with N-octyl-O-sulfate chitosan for enhanced nephroprotective effect

Article

Author: Gao, Leiping ; Gao, Fuping ; Gu, Mingjia ; Wei, Qingxue ; Zhang, Hang ; Bao, Rui ; Zhang, Jian ; Gao, Hong ; Shen, Qiusheng ; Wang, Jiapeng

Natural occurring anthraquinone like chrysophanol has been studied because of its anti-diabetic, anti-tumor, anti-inflammatory, hepatoprotective and neuroprotective properties. Nonetheless, its poor water solubility and unstable nature are big concerns in achieving efficient delivery and associated pharmacokinetic and pharmacodynamic effects. Herein, this study sought to solve the above-mentioned problem through development of chrysophanol-loaded nanoparticles to enhance the bioavailability of chrysophanol and to evaluate its anti-renal fibrosis effect in rats. After synthesis of a safe N-octyl-O-sulfate chitosan, we used it to prepare chrysophanol-loaded nanoparticles through dialysis technique before we performed and physical characterization. Also, we tested the stability of the nanoparticles for 21 days at 4 °C and room temperature (25 °C) and evaluated their pharmacokinetics and anti-renal fibrosis effect in rat model of chronic kidney disease (CKD). In terms of results, the nano-preparation demonstrated an acceptable narrow size distribution, wherein the encapsulation rate, size, polydispersed index (PDI) and electrokinetic potential at room temperature were respectively 83.41±0.89 %, 364.88±13.62 nm, 0.192±0.015 and 23.78±1.39 mV. During 21 days of storage, we observed that size of particles and electrokinetic potential altered slightly but the difference was statistically insignificant (p > 0.05). Also, in vitro release studies showed that the formulation reached 84.74 % at 24 h. Chrysophanol nanoparticles showed a 2.57-fold increase in bioavailability compared to unformulated chrysophanol. More importantly, chrysophanol nanoparticles demonstrated certain renal internalization properties and anti-renal fibrosis effects, which could ultimately result in reduced blood-urea nitrogen (BUN), kidney-injury molecule-1 (KIM-1) and serum creatinine (SCr) levels in model rats. In conclusion, the prepared chrysophanol-loaded nanoparticles potentially increased bioavailability and enhanced nephroprotective effects of chrysophanol.

Journal of Inflammation

Sodium pyruvate exerts protective effects against cigarette smoke extract-induced ferroptosis in alveolar and bronchial epithelial cells through the GPX4/Nrf2 axis

Article

Author: Chang, Jingwen ; He, Liwei ; Zhang, Zijin ; Jiang, Zhijun ; Fan, Fangtian ; Xu, Zhao ; Hou, Xianbang ; Zhao, Ziwen ; Song, Xiaoyu

AbstractBackgroundFerroptosis in alveolar and bronchial epithelial cells is one of the main mechanisms underlying the development of chronic obstructive pulmonary disease (COPD). Sodium pyruvate (NaPyr) is a natural antioxidant in the body, exhibiting anti-inflammatory and antioxidant activities. NaPyr has been used in a Phase II clinical trial as a novel therapy for COPD; however, the mechanism underlying NaPyr-mediated therapeutic benefits in COPD is not well understood.ObjectiveWe aimed to assess the protective effects of NaPyr and elucidate its potential mechanism in cigarette smoke extract (CSE)-induced ferroptosis.To minic the inflammatory response and ferroptosis triggered by cigarette smoke in COPD in an invitro cell based system, we expose a human bronchial epithelial cells to CSE.MethodsTo minic the inflammatory response and ferroptosis triggered by cigarette smoke in COPD in an invitro cell based system, the A549 (human lung carcinoma epithelial cells) and BEAS-2B (bronchial epithelial cells) cell lines were cultured, followed by treatment with CSE. To measure cellular viability and iron levels, we determined the levels of malondialdehyde (MDA), glutathione (GSH), reactive oxygen species (ROS), mitochondrial superoxide (MitoSOX), membrane potential (MMP), and inflammatory factors (tumor necrosis factor [TNF] and interleukin [IL]-8), and examined CSE-induced pulmonary inflammation and ferroptosis. To clarify the molecular mechanisms of NaPyr in COPD therapy, we performed western blotting and real-time PCR (qPCR) to determine the expression of glutathione peroxidase 4 (GPX4), nuclear factor E2-related factor 2 (Nrf2), and cyclooxygenase 2 (COX2).ResultsWe found that NaPyr effectively mitigated CSE-induced apoptosis and improved apoptosis induced by erastin, a ferroptosis inducer. NaPyr significantly decreased iron and MDA levels and increased GSH levels in CSE-induced cells. Furthermore, NaPyr suppressed ferroptosis characteristics, such as decreased levels of ROS, MitoSOX, and MMP. NaPyr significantly increases the expression levels of GPX4 and Nrf2, indicating that activation of the GPX4/Nrf2 axis could inhibit ferroptosis in alveolar and bronchial epithelial cells. More importantly, NaPyr inhibited the secretion of downstream inflammatory factors, including TNF and IL-8, by decreasing COX2 expression levels to suppress CSE-induced inflammation.ConclusionAccordingly, NaPyr could mitigate CSE-induced ferroptosis in alveolar and bronchial epithelial cells by activating the GPX4/Nrf2 axis and decreasing COX2 expression levels. In addition, NaPyr reduced the secretion of inflammatory factors (TNF and IL-8), affording a novel therapeutic candidate for COPD.Graphical Abstract

100 Deals associated with Pharmamax Pharmaceuticals Ltd.

Login to view more data

100 Translational Medicine associated with Pharmamax Pharmaceuticals Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

Phase 1 Clinical

Phase 2 Clinical

1

Phase 3 Clinical

Approved

1

9

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fluoxetine Hydrochloride/Olanzapine ( D1 receptor x D2 receptor x SERT )	Bipolar and Related Disorders More	Approved
Arformoterol Tartrate ( β2-adrenergic receptor )	Pulmonary Disease, Chronic Obstructive More	Phase 3
Sodium Pyruvate ( IL-6 x Reactive oxygen species )	Pulmonary Disease, Chronic Obstructive More	Phase 2
Morphine Sulfate/Naltrexone Hydrochloride ( Opioid receptors )	Cancer Pain More	Phase 1
PC-0003	-	IND Application